Published

C29-12 Psilocybin Treatment Could Improve Outcomes for Age-associated Lung Diseases

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: American Journal of Respiratory and Critical Care Medicine
Date: 2026-05-01
Source: Crossref
DOI: 10.1093/ajrccm/aamag162.144
PubMed: Unavailable

Authors

Hecker L Kleinhenz J M Coarfa C Kato K

Watch author

Derived topics and classifications

psilocybin psilocin Mechanism of Action Aging Telomeres Cellular Senescence Oxidative Stress Animal Study Older Adults Proteomics Inflammation Animal Study

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

C29-12 Psilocybin Treatment Could Improve Outcomes for Age-associated Lung Diseases2026-05-01

Related papers

An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-07-23 A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17